Syndax Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 35
Employees
  • Stock Symbol
  • SNDX
Stock Symbol
  • Share Price
  • $17.28
  • (As of Monday Closing)

Syndax General Information

Description

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 35 Gatehouse Drive
  • Building D, Floor 3
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Syndax Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Syndax Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.28 $17.60 $5.35 - $21.97 $666M 38.5M 357K -$1.82

Syndax Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 456,500 167,058 20,921 93,062
Revenue 1,516 1,517 1,517 2,108
EBITDA (58,674) (57,526) (75,825) (62,147)
Net Income (59,127) (56,047) (73,961) (60,802)
Total Assets 192,628 63,525 83,938 137,186
Total Debt 20,563 897 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Syndax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination
Drug Discovery
Waltham, MA
35 As of 2019
00000
000000000 00000

000000 0

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

0000000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000 000000000
Heidelberg, Germany
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syndax Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Jounce Therapeutics Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
0000 000000 Formerly PE-Backed Vancouver, Canada 00 00000 00000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
You’re viewing 5 of 27 competitors. Get the full list »

Syndax Executive Team (21)

Name Title Board Seat Contact Info
Briggs Morrison MD Chief Executive Officer & Board Member
Daphne Karydas Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Richard Shea Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michael Metzger Chief Operating Officer, Operations & Board Member
Peter Ordentlich Ph.D Chief Scientific Officer & Founder
You’re viewing 5 of 21 executive team members. Get the full list »

Syndax Board Members (20)

Name Representing Role Since
Arthur Pappas Pappas Capital Board Member 000 0000
Briggs Morrison MD Syndax Chief Executive Officer & Board Member 000 0000
Dennis Podlesak Self Chairman & Board Member 000 0000
Fabrice Egros Ph.D Self Chairman 000 0000
Jennifer Jarrett Self Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Syndax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syndax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial